PaxVax raises $22M for PhIII trial of cholera vaccine

PaxVax has raised $22 million in venture capital funding to advance development of its oral cholera vaccine, PXVX0200. The investment gives PaxVax the cash to run a 3,000-patient Phase III trial of the product. If successful, PXVX0200 would become the first FDA-approved cholera vaccine for those visiting high-risk regions. Article